FLGLF4: You're probably right, statistically speaking. Those options are pretty much on the radar for every small cash-strapped biotech. 98% of them never come up with a deal, so they PIPE you. What else can they do? PPHM was lucky they were able to borrow money last time in this difficult financing environment. PPHM would not be considered too big to fail, thus they're not eligible for free government money. In my years of biotech investing I've been hit in the head with so many PIPES I'm surprised I'm still alive. Biotech is not for the impatient, and it is smart not to risk any more than you can afford to lose. It isn't really investing, it's gambling. But it is interesting. It would be nice if PPHM could be one of the few success stories.
Market Data 
Markets 
AI
